Eligible patients can save up to $6000 annually with no monthly limit

VEMLIDY Co-pay Coupon Program

VEMLIDY Co-pay Coupon Program

  • Eligible patients with commercial insurance may pay as low as a $0 co-pay for out-of-pocket costs for VEMLIDY, up to $6000 per year with no monthly limit, with the VEMLIDY Co-pay Coupon Program*
Go to Patient Enrollment

For multilingual assistance call:
1-855-769-7284 Monday–Friday,
9 AM–8 PM ET

As low as $0 co-pay
*Co-pay coupon support is available for commercially insured eligible patients only. Additional restrictions may apply. Subject to change; for full terms and conditions, visit www.mysupportpath.com/providers. This is not health insurance. Only accepted at participating pharmacies.

Share this brochure with patients who may need help affording treatment

  • Provides helpful information for eligible patients who may need assistance affording their co-pay costs
  • Includes language translations for traditional Chinese, Vietnamese, and Korean
  • As of 7/1/23, eligible patients can save up to $6000 annually with no monthly limit. The downloadable PDF may not reflect the latest information. Contact Support Path with any questions*
Download PDF

For multilingual assistance call:
1-855-769-7284 Monday–Friday,
9 AM–8 PM ET

Image of Co-pay Coupon Program brochure
*Co-pay coupon support is available for commercially insured eligible patients only. Additional restrictions may apply. Subject to change; for full terms and conditions, visit www.mysupportpath.com/providers. This is not health insurance. Only accepted at participating pharmacies.

Help patients understand insurance coverage and financial support options

Support Path®

Do your patients worry about cost? Insurance or no insurance, Support Path may be able to help.

Support Path provides information to help facilitate patient access to medication. Whether they have insurance or not, Support Path can explore potential coverage options that might be right for them. In some cases, patient consent is required before Support Path can provide assistance.

Support Path can provide information on the following topics:

  • Benefits investigation
  • Prior authorization and appeals process information
  • Patient Assistance Program for eligible uninsured patients
  • Co-pay Coupon Program*

Help your patients enroll

For multilingual assistance call:
1-855-769-7284 Monday–Friday,
9 AM–8 PM ET

Support Path® Program
*Co-pay coupon support is available for commercially insured eligible patients only. Additional restrictions may apply. Subject to change; for full terms and conditions, visit www.mysupportpath.com/providers. This is not health insurance. Only accepted at participating pharmacies.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: POSTTREATMENT SEVERE ACUTE EXACERBATION OF HEPATITIS B

  • Discontinuation of anti-hepatitis B therapy, including VEMLIDY, may result in severe acute exacerbations of hepatitis B. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VEMLIDY. If appropriate, resumption of anti-hepatitis B therapy may be warranted.

Warnings and Precautions

  • Risk of Development of HIV-1 Resistance in HBV/HIV-1 Coinfected Patients: Due to this risk, VEMLIDY alone should not be used for the treatment of HIV-1 infection. Safety and efficacy of VEMLIDY have not been established in HBV/HIV-1 coinfected patients. HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with VEMLIDY, and, if positive, an appropriate antiretroviral combination regimen that is recommended for HBV/HIV-1 coinfected patients should be used.
  • New Onset or Worsening Renal Impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with TAF-containing products. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue VEMLIDY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Monitor renal function in all patients – See Dosage and Administration.
  • Lactic Acidosis and Severe Hepatomegaly with Steatosis: Fatal cases have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (TDF). Discontinue VEMLIDY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.

Adverse Reactions

Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 144 were headache, upper respiratory tract infection, abdominal pain, cough, back pain, arthralgia, fatigue, nausea, diarrhea, dyspepsia, and pyrexia.

Drug Interactions

  • Coadministration of VEMLIDY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of tenofovir and the risk of adverse reactions.
  • Coadministration of VEMLIDY is not recommended with the following: oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, or St. John’s wort. Such coadministration is expected to decrease the concentration of tenofovir alafenamide, reducing the therapeutic effect of VEMLIDY. Drugs that strongly affect P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) activity may lead to changes in VEMLIDY absorption.

Consult the full prescribing information for VEMLIDY for more information on potentially significant drug interactions, including clinical comments.

Dosage and Administration

  • Testing Prior to Initiation: HIV infection.
  • Prior to or When Initiating, and During Treatment: On a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus.
  • Dosage in Adults: 1 tablet taken once daily with food.
  • Renal Impairment: Not recommended in patients with end stage renal disease (ESRD; eCrCl <15 mL/min) who are not receiving chronic hemodialysis; in patients on chronic hemodialysis, on hemodialysis days, administer VEMLIDY after completion of hemodialysis treatment.
  • Hepatic Impairment: Not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.

INDICATION

VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Please see full Prescribing Information for VEMLIDY, including BOXED WARNING.